Los Angeles Capital Management LLC Allogene Therapeutics, Inc. Transaction History

Los Angeles Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$2.23 - $4.38 $79,372 - $155,897	-35,593 Reduced 22.16%	125,030 $291,000
Q1 2024 Apr 05, 2024	SELL	$2.92 - $5.63 $15,636 - $30,148	-5,355 Reduced 3.23%	160,623 $717,000
Q4 2023 Feb 06, 2024	BUY	$2.28 - $3.5 $378,429 - $580,923	165,978 New	165,978 $532,000
Q2 2023 Aug 03, 2023	BUY	$4.53 - $6.74 $186,758 - $277,869	41,227 New	41,227 $204,000
Q4 2021 Feb 03, 2022	SELL	$13.13 - $24.52 $331,965 - $619,939	-25,283 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$21.01 - $27.64 $109,882 - $144,557	-5,230 Reduced 17.14%	25,283 $650,000
Q2 2021 Aug 05, 2021	SELL	$23.49 - $35.8 $72,513 - $110,514	-3,087 Reduced 9.19%	30,513 $796,000
Q1 2021 May 05, 2021	SELL	$25.79 - $39.02 $274,276 - $414,977	-10,635 Reduced 24.04%	33,600 $1.19 Million
Q4 2020 Feb 04, 2021	SELL	$25.24 - $43.45 $22,716 - $39,105	-900 Reduced 1.99%	44,235 $1.12 Million
Q3 2020 Nov 02, 2020	SELL	$32.38 - $44.96 $110,739 - $153,763	-3,420 Reduced 7.04%	45,135 $1.7 Million
Q2 2020 Aug 05, 2020	BUY	$18.39 - $54.04 $892,926 - $2.62 Million	48,555 New	48,555 $2.08 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.